SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 7 — Focused Visit (Care-plan review) — Billie Holiday — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientBillie Holiday
Date of birth1915-04-07
IdentifiersMRN HR-ML010-SYN-TD; SSN (made up) 000-10-4472
Document date1948-10-19
AuthorConstance Mayfield, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Six-month recovery, alcohol, liver, and mood review. [S]

History of Present Illness

Ms. Holiday returns six months after starting buprenorphine. She has taken 16 mg every day since the return to use before the three-month visit and has used no heroin or other opioids for three months. The early refill and travel letter worked on her last tour. She drinks one drink on some performance nights and none otherwise. Her dental abscess was drained by the dentist the week of her sick visit, and the tooth has since had root canal treatment; she finished the amoxicillin and needed the pain tablets for only three days. She sleeps better and enjoys singing again. She sees her counselor weekly and her peer recovery coach every two weeks. [S]

ElementDetail
Opioid useNone for three months
Buprenorphine16 mg daily, no gaps
AlcoholOne drink on some performance nights
ToothAbscess drained; root canal completed; no pain
MoodPHQ-9 4

Review of Systems

SystemResultFinding
ConstitutionalNegativeEnergy better; weight up 1.6 kg
Ears, nose, mouth, and throatNegativeNo tooth pain or swelling
PsychiatricNegativeMood good; PHQ-9 score 4; no thoughts of suicide or self-harm

3 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Buprenorphine 8 mg and naloxone 2 mg sublingual film: half a film (4 mg) on day 1, then one film (8 mg) under the tongue dailyOne film under the tongue daily after a 4 mg first doseSublingual route1948-04-20 to 1948-04-27completedS
Buprenorphine 8 mg and naloxone 2 mg sublingual film, two films (16 mg) under the tongue once dailyTwo films under the tongue once dailySublingual route1948-04-27activeS
Naloxone 4 mg nasal spray, one spray in one nostril for a suspected opioid overdose; may repeat every 2 to 3 minutes in alternating nostrils; call 911One spray (4 mg) in one nostril for suspected overdose; repeat every 2 to 3 minutes if there is no responseNasal route1948-04-20activeS
Acamprosate 333 mg delayed-release oral tablet, two tablets (666 mg) by mouth three times dailyTwo tablets by mouth three times dailyOral route1948-04-27activeS
Thiamine 100 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route1948-04-20 to 1948-10-19completedS
Amoxicillin 500 mg oral capsule, one capsule by mouth three times daily for seven daysOne capsule by mouth three times daily for seven daysOral route1948-09-21 to 1948-09-28completedS
Ibuprofen 400 mg oral tablet, one tablet by mouth every 6 to 8 hours with food as needed for tooth pain, for up to five daysOne tablet by mouth every 6 to 8 hours with food as needed, up to five daysOral route1948-09-21 to 1948-09-26completedS
Acetaminophen 500 mg oral tablet, two tablets by mouth every 8 hours as needed for tooth pain, no more than 3,000 mg a day, for up to five daysTwo tablets by mouth every 8 hours as needed, up to 3,000 mg a dayOral route1948-09-21 to 1948-09-26completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1948-10-19Body height165cmS
1948-10-19Body weight69kgS
1948-10-19Body mass index (BMI) [Ratio]25.3kg/m2S
1948-10-19Systolic blood pressure116mm[Hg]S
1948-10-19Diastolic blood pressure74mm[Hg]S
1948-10-19Heart rate72/minS
1948-10-19Respiratory rate14/minS
1948-10-19Body temperature36.6CelS
1948-10-19Oxygen saturation in Arterial blood by Pulse oximetry99%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1948-10-19Hemoglobin [Mass/volume] in Blood12.9g/dL11.6-15 g/dLNormalS
1948-10-19MCV [Entitic mean volume] in Red Blood Cells by Automated count95fL80-100 fLNormalS
1948-10-19Platelets [#/volume] in Blood by Automated count24810*3/uL150-400 10*3/uLNormalS
1948-10-19Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma30U/L10-40 U/LNormalS
1948-10-19Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma26U/L7-56 U/LNormalS
1948-10-19Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma34U/L5-40 U/LNormalS
1948-10-19Phosphatidylethanol [Mass/volume] in Blood22ng/mLBelow 20 ng/mL: abstinence or light drinking; 20 to 199: significant drinking; 200 or more: heavy drinkingHighS
1948-10-19Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]4{score}S

Physical Exam

Vital signs recorded on 1948-10-19; see the Vital Signs section. [S]

SystemFinding
GeneralWell; blood pressure 116/74, pulse 72
MouthTreated lower right molar; no swelling
AbdomenSoft; no liver enlargement
PsychiatricBright and engaged; no signs of intoxication or withdrawal

Problems

ProblemClinical statusVerificationCodeProvenance
Opioid use disorder (heroin), severe; in early remission in a controlled environment at intake, five weeks after release from custody; on buprenorphine; synthetic modern episode linked to her documented heroin useactiveconfirmed F11.20S — Synthetic modern coding of the documented heroin addiction; language is person-first, and the code does not change with a return to use.
Alcohol use disorder, moderate; synthetic modern episode linked to her documented heavier drinking after her mother's deathactiveconfirmed F10.20S — Synthetic modern coding of the documented drinking; the liver disease reported in her last year is not coded, because it was documented long after the episode.
Acute periapical abscess of the lower right first molar with localized swelling, treated with an antibiotic and dental drainage; resolvedresolvedconfirmed K04.7S — Synthetic acute dental infection; not a historical claim.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
Medication safetyBuprenorphine dose, adherence, cravings, withdrawal, and side effectsEvery visitCompleted today16 mg daily without gaps; no cravings this month
Self-managementVisit frequencyEvery 1 to 2 weeks in the first month after starting, then every 2 to 4 weeks until stableCompleted todayStable; monthly visits from now
LaboratoryUrine drug testing, including fentanyl, explained as part of care rather than as a test of trustAt the start, then about monthly early in treatment and as neededCompleted todayBuprenorphine and norbuprenorphine only
Medication safetyPrescription drug monitoring program checkBefore each buprenorphine prescriptionCompleted todayOnly the dental prescriptions from the sick visit, which were not opioids
Medication safetyNaloxone at home and in her bag, and a trained companionAt the start; check and replace at each visitCompleted todayIn date at home and in her bag
Medication safetyPrescription continuity on tour (pharmacy, prior authorization, travel letter)Before each tourCompleted todayEarly fill and travel letter worked on the last tour
Self-managementCounseling and peer recovery supportOffered to everyone; not a condition of medicationCompleted todayCounseling weekly; peer coach every two weeks
Self-managementOral care on sublingual buprenorphineAt the start and yearlyCompleted todayAbscess treated; dental review every six months
SurveyDrinking and PEthPEth at intake and at each check while drinking continues; AUDIT-C yearlyCompleted todayPEth 22 ng/mL; AUDIT-C 3 at the preventive visit
Medication safetyAcamprosate adherence and kidney functionKidney function before starting; adherence every visitCompleted todayTaking all three doses
Medication safetyThiamineWhile drinking heavilyCompleted todayStopped today; drinking is light
LaboratoryLiver tests (AST, ALT, GGT, albumin, bilirubin)At intake, then every 1 to 3 months while drinking is heavy, and yearlyCompleted todayAST 30, ALT 26, GGT 34 U/L, normal
LaboratoryBlood countAt intake and with liver tests while drinkingCompleted todayHemoglobin 12.9 g/dL, MCV 95 fL (from 101), platelets 248
LaboratoryFIB-4 fibrosis scoreAt intake; repeat in 6 to 12 months with ongoing drinking, and every 1 to 2 yearsCompleted today0.78, low risk; repeat yearly
ImagingVibration-controlled transient elastographyIf FIB-4 is 1.3 or higherNot indicatedFIB-4 below 1.3
LaboratoryHepatitis C, hepatitis B, and HIV testingAt entry to care, then yearly while any drug use continuesDueNonreactive at intake; repeat at the intake anniversary
Self-managementHepatitis A and B vaccinesHepatitis B two doses 4 weeks apart; hepatitis A two doses 6 months apartCompleted todayHepatitis A dose 2 given today; both series complete
Self-managementInfluenza vaccineEach autumnCompleted todayGiven today
SurveyDepression screen (PHQ-9)At intake and at each recovery visit while symptoms are presentCompleted todayPHQ-9 4, from 9 at intake and 11 at three months
SurveySuicide and overdose risk review, safety plan, and the 988 Suicide & Crisis LifelineEvery visitCompleted todayNo thoughts of suicide or self-harm; the 988 Suicide & Crisis Lifeline in her phone

Goal progress:

Immunizations given today: Hepatitis A vaccine, adult, dose 2 of 2; Influenza vaccine, 1948-1949 season [S]

Guideline basis: The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update (2020); Treatment Options for Substance Use Disorder (medications for opioid and alcohol use disorders) (2026); VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders (2021); Diagnosis and Treatment of Alcohol-Associated Liver Diseases: 2019 Practice Guidance From the American Association for the Study of Liver Diseases (2019); AASLD Practice Guideline on blood-based noninvasive liver disease assessment of hepatic fibrosis and steatosis (2025); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); Adult Immunization Schedule by Medical Condition and Other Indication (2026); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026)

Follow-up: Monthly buprenorphine visits. Counseling weekly. Liver tests, FIB-4, and infection screening at one year. [S]